Oral treatment for paroxysmal nocturnal hemoglobinuria
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests an oral medication (MY008211A) designed to reduce red blood cell destruction in people with paroxysmal nocturnal hemoglobinuria (PNH). The trial aims to see if the drug is safe and effective in improving anemia and lowering markers of disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have a body mass index (BMI) of at least 18.
- You have been diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) confirmed by a special blood test showing that at least 10% of your blood cells are affected.
- Your blood hemoglobin level is below 100 g/L (this is low, indicating anemia).
- Your LDH level (a marker of red blood cell breakdown) is higher than 1.5 times the upper limit of normal.
- Before starting the study, you must have received vaccinations against certain bacterial infections (meningococcus, and possibly pneumococcus and Haemophilus influenzae).
- You have not had a bone marrow or stem cell transplant, and you have not had your spleen removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks the long-term safety of the drug MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH). It is only for those who already took the drug in an earlier study and had benefit, and who have had specific vaccines.
This study tests a new medicine called VSA012 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. The goal is to see if VSA012 can help manage symptoms like fatigue and low blood counts better than the current standard treatment.
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
This study tests a new medicine called SLN12140 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It aims to see if the drug can help manage the disease and improve symptoms.
This study tests an investigational oral medication called TUL321 in healthy volunteers to see if it is safe and how the body handles it. It may help understand the drug's effects and is an early step in developing a new treatment.
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria (PNH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.